Skip to main content
. 2022 Apr 29;12:7002. doi: 10.1038/s41598-022-10938-x

Figure 2.

Figure 2

Kaplan–Meier survival curves of overall survival (OS) between PPI and H2RA groups in gefitinib (A) and erlotinib (B); and time to next treatment (TTNT) between PPI and H2RA groups in gefitinib (C) and erlotinib (D).